Ray Dalio’s Alnylam Pharmaceuticals ALNY Stock Holding History

Ray Dalio’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$35.3M	Buy	106,592 +20,975	+24%	+$7.14M	0.16%	95
2025 Q4	$34M	Buy	85,617 +51,706	+152%	+$22.9M	0.12%	131
2025 Q3	$15.5M	Buy	+33,911	New	+$13.8M	0.06%	249
2025 Q1	–	Sell	-6,452	Closed	-$1.52M	–	674
2024 Q4	$1.52M	Buy	6,452 +4,450	+222%	+$1.17M	0.01%	467
2024 Q3	$551K	Buy	+2,002	New	+$521K	﹤0.01%	681
2024 Q1	–	Sell	-1,951	Closed	-$373K	–	684
2023 Q4	$373K	Buy	1,951 +65	+3%	+$11.1K	﹤0.01%	723
2023 Q3	$334K	Buy	1,886 +90	+5%	+$17.2K	﹤0.01%	718
2023 Q2	$341K	Buy	1,796 +541	+43%	+$107K	﹤0.01%	674
2023 Q1	$251K	Buy	+1,255	New	+$264K	﹤0.01%	689
2022 Q4	–	Sell	-1,283	Closed	-$257K	–	823
2022 Q3	$257K	Sell	1,283 -229	-15%	-$43.7K	﹤0.01%	835
2022 Q2	$221K	Buy	+1,512	New	+$215K	﹤0.01%	967
2021 Q4	–	Sell	-2,234	Closed	-$422K	–	734
2021 Q3	$422K	Sell	2,234 -3,865	-63%	-$725K	﹤0.01%	604
2021 Q2	$1.03M	Buy	+6,099	New	+$893K	0.01%	581

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Ray Dalio's ALNY Position: Q1 2026 in Review

Ray Dalio increased its Alnylam Pharmaceuticals (ALNY) stake by 24% in Q1 2026, buying an estimated $7.14M and bringing the position to 106,592 shares worth $35.3M. The position accounts for 0.16% of the portfolio, ranked #95.

Ray Dalio first reported a position in ALNY in Q2 2021 and has held it in 13 quarters since. 789 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

Ray Dalio held 106,592 shares of Alnylam Pharmaceuticals worth $35.3M as of Q1 2026.
Ray Dalio bought 20,975 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $7.14M.
Alnylam Pharmaceuticals made up 0.16% of Ray Dalio's portfolio in Q1 2026, its #95 holding.
Ray Dalio first reported a position in Alnylam Pharmaceuticals in Q2 2021 and has held it in 13 quarters since.
789 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Bridgewater Associates's 13F filing for Q1 2026, filed 15 May 2026.